Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication AMLSG 16-10

Trial Profile

Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication AMLSG 16-10

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Midostaurin (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AMLSG16-10
  • Most Recent Events

    • 25 Jun 2017 Results assessing FLT3mut status at the time of diagnosis, refractory disease and relapse in acute myeloid leukemia patients treated within the CALGB 10603 (RATIFY, NCT00651261) and AMLSG 16-10 (NCT01477606) trial presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results assessing clone evolution of Flt3-Itd positive acute myeloid leukemia at diagnosis and relapse in patients treated within the Calgb 10603 (Ratify, NCT00651261) and Amlsg 16-10 (NCT01477606) trials presented at the 22nd Congress of the European Haematology Association
    • 09 Nov 2016 Time frame of endpoint has been changed from 4 years to 7.5 years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top